Hüttl, M.; Markova, I.; Miklankova, D.; Zapletalova, I.; Poruba, M.; Haluzik, M.; Vaněčkova, I.; Malinska, H.
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. Int. J. Mol. Sci. 2021, 22, 11513.
https://doi.org/10.3390/ijms222111513
AMA Style
Hüttl M, Markova I, Miklankova D, Zapletalova I, Poruba M, Haluzik M, Vaněčkova I, Malinska H.
In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. International Journal of Molecular Sciences. 2021; 22(21):11513.
https://doi.org/10.3390/ijms222111513
Chicago/Turabian Style
Hüttl, Martina, Irena Markova, Denisa Miklankova, Iveta Zapletalova, Martin Poruba, Martin Haluzik, Ivana Vaněčkova, and Hana Malinska.
2021. "In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia" International Journal of Molecular Sciences 22, no. 21: 11513.
https://doi.org/10.3390/ijms222111513
APA Style
Hüttl, M., Markova, I., Miklankova, D., Zapletalova, I., Poruba, M., Haluzik, M., Vaněčkova, I., & Malinska, H.
(2021). In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia. International Journal of Molecular Sciences, 22(21), 11513.
https://doi.org/10.3390/ijms222111513
